Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company, announced it will present new preclinical data from its Rejuva® platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC). The presentation will focus on the feasibility and safety of novel endoscopic ultrasound-guided delivery of human GLP-1 pancreatic gene therapy in pigs. The session is scheduled for December 12, 2024, from 6:30 pm to 7:30 pm (PST).
The company specializes in developing new approaches to treat root causes of obesity and Type 2 Diabetes (T2D) through their single-administration Smart GLP-1 Pancreatic Gene Therapy Platform.
Fractyl Health (Nasdaq: GUTS), un'azienda di terapie metaboliche, ha annunciato che presenterà nuovi dati preclinici dalla sua piattaforma Rejuva® durante la Sessione Poster del 22° Congresso Mondiale sulla Resistenza all'Insulina, Diabete e Malattie Cardiovascolari (WCIRDC) del 2024. La presentazione sarà incentrata sulla fattibilità e sicurezza della nuova terapia genica pancreatica umana GLP-1 guidata da ultrasuoni endoscopici nei maiali. La sessione è programmata per il 12 dicembre 2024, dalle 18:30 alle 19:30 (PST).
L'azienda è specializzata nello sviluppo di nuovi approcci per trattare le cause principali dell'obesità e del Diabete di Tipo 2 (T2D) attraverso la loro piattaforma di terapia genica pancreatica Smart GLP-1 ad assunzione singola.
Fractyl Health (Nasdaq: GUTS), una empresa de terapias metabólicas, anunció que presentará nuevos datos preclínicos de su plataforma Rejuva® en la Sesión de Posters del 22° Congreso Mundial sobre Resistencia a la Insulina, Diabetes y Enfermedades Cardiovasculares (WCIRDC) 2024. La presentación se centrará en la viabilidad y seguridad de la novedosa terapia génica pancreática humana GLP-1 administrada por ultrasonido endoscópico en cerdos. La sesión está programada para el 12 de diciembre de 2024, de 18:30 a 19:30 (PST).
La empresa se especializa en desarrollar nuevos enfoques para tratar las causas raíz de la obesidad y la Diabetes Tipo 2 (T2D) a través de su plataforma de terapia génica pancreática Smart GLP-1 de administración única.
Fractyl Health (Nasdaq: GUTS), 대사 치료제 회사가 2024년 제22회 세계 인슐린 저항성, 당뇨병 및 심혈관 질환(WCIRDC) 포스터 세션에서 Rejuva® 플랫폼의 새로운 전임상 데이터를 발표할 것이라고 발표했습니다. 발표는 돼지에서의 인간 GLP-1 췌장 유전자 치료의 내시경 초음파 유도 전달의 실행 가능성 및 안전성에 초점을 맞출 것입니다. 이 세션은 2024년 12월 12일 오후 6시 30분부터 7시 30분까지(PST) 예정되어 있습니다.
이 회사는 단일 투여 Smart GLP-1 췌장 유전자 치료 플랫폼을 통해 비만과 제2형 당뇨병(T2D)의 근본 원인을 치료하기 위한 새로운 접근 방식을 개발하는 데 전문화되어 있습니다.
Fractyl Health (Nasdaq: GUTS), une entreprise de thérapies métaboliques, a annoncé qu'elle présentera de nouvelles données précliniques de sa plateforme Rejuva® lors de la session des posters du 22e Congrès mondial sur la résistance à l'insuline, le diabète et les maladies cardiovasculaires (WCIRDC) en 2024. La présentation se concentrera sur la faisabilité et la sécurité de l'administration guidée par ultrasons endoscopiques de la thérapie génique pancréatique humaine GLP-1 chez les porcs. La session est prévue pour le 12 décembre 2024, de 18h30 à 19h30 (PST).
L'entreprise est spécialisée dans le développement de nouvelles approches pour traiter les causes profondes de l'obésité et du diabète de type 2 (T2D) grâce à sa plateforme de thérapie génique pancréatique Smart GLP-1 à administration unique.
Fractyl Health (Nasdaq: GUTS), ein Unternehmen für metabolische Therapien, gab bekannt, dass es neue präkklinische Daten von seiner Rejuva®-Plattform auf der Poster-Session des 22. Weltkongresses für Insulinresistenz, Diabetes und Herz-Kreislauf-Erkrankungen (WCIRDC) 2024 präsentieren wird. Die Präsentation wird sich auf die Machbarkeit und Sicherheit der neuartigen endoskopisch-ultraschallgesteuerten Verabreichung von menschlicher GLP-1-Pankreasgen-Therapie bei Schweinen konzentrieren. Die Sitzung ist für den 12. Dezember 2024, von 18:30 bis 19:30 Uhr (PST) angesetzt.
Das Unternehmen hat sich darauf spezialisiert, neue Ansätze zu entwickeln, um die Ursachen von Fettleibigkeit und Typ-2-Diabetes (T2D) über ihre einmalige Smart GLP-1-Pankreasgen-Therapie-Plattform zu behandeln.
- Development of innovative GLP-1 pancreatic gene therapy platform targeting obesity and Type 2 Diabetes
- None.
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place December 12-14, 2024.
Details of the session are below:
- Poster Title: Feasibility and Safety of Novel Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in Pigs
- Presentation Date & Time: Thursday, December 12, 2024, 6:30 pm - 7:30 pm (PST)
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or https://twitter.com/FractylHealth.
About Rejuva
Fractyl Health’s Rejuva platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com, 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Stephen Jasper Gilmartin Group
stephen@gilmartinir.com, 619.949.3681
FAQ
What will Fractyl Health (GUTS) present at WCIRDC 2024?
When is Fractyl Health's (GUTS) presentation at WCIRDC 2024?
What therapeutic areas does Fractyl Health (GUTS) target with their Rejuva platform?
